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Abstract
Metabolomics, defined as the comprehensive analysis of compounds in a biological 
specimen, is an emerging technology that helps several pathologies to inform about 
new biomarkers. Metabolic diseases comprise a group of rare conditions that in total 
represent an important health problem. Historically, small numbers of metabolites have 
been used to diagnose complex metabolic diseases such as diabetes or metabolic dis-
eases. Metabolomic methodology, due to the evolution of clinical chemistry technologies, 
could detect thousands of organic compounds. In this way, metabolomic approach gives 
information of metabolic pathways describing physiopathology that underlies disease, 
including the possibility of discovery of new markers that could be used to diagnose 
or check the efficacy of the treatments. Diabetes, classic inborn error of metabolism as 
methylmalonic aciduria, lysosomal diseases and rare optic neuropathy affecting adults 
are discussed in this chapter.
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1. Introduction
Rare metabolic diseases comprise a group of more than 7000 conditions that are particularly 
rare, but in total, they represent an important health problem. There is no single, internation-
ally accepted definition of a rare metabolic disease; currently, it is a syndrome that occurs 
in one child per 200,000 births. In Europe, they are supposed to affect 7% of the population. 
Nowadays, as less than 500 metabolic diseases have available and effective treatments, new 
therapeutic solutions should be developed.
New approach and initiatives are necessary to advance research for patients suffering from 
an inborn error of metabolism because governments pay little attention due to their costs and 
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low incidences. Suitable and quick diagnosis is basic to the patients, even if there is no treat-
ment, since it reduces the overdiagnosis, followed by suitable care, can improve quality of life 
for these patients.
The inherited metabolic diseases are biochemical defects diagnosed routinely by neonatal 
screening programmes. This successful screening methodology continues to broaden and 
improve, and new biomarkers are added depending on the country.
Metabolomics is an “omics” science focused on dynamic biology ruled by organic metabo-
lites. A metabolome is defined as the group of metabolites detected and playing in the same 
metabolic pathway in the normal functioning of the cell. Metabolomics complements other 
analytical sciences as proteomics or genomics. Physiological changes that are consequences of 
a special gene expression are characterised by a variation in the metabolic compounds. Thus, 
the metabolome is more sensitive than the transcriptome or the proteome. A small variation 
in protein expression can have a significant effect on the activity of the metabolic pathway and 
the concentration of the relevant metabolites.
In summary, the workflow for metabolomics applied to metabolic diseases starts with model 
design or patients selection (inclusion/exclusion criteria), sample preparation and separation-
detection of metabolites by chromatography and mass spectrometry, respectively. Then, the 
obtained information has to be aligned and identified in order to carry out the statistics. The 
last step in this methodology is to obtain useful biomarkers for each inborn error of metabo-
lism (Figure 1).
The aim of this chapter is to show the utility of metabolomics, applying to diabetes and inborn 
error of metabolism. The latter ones traditionally with difficult diagnosis and uncertain treat-
ment are due to their low incidence. However, the metabolomic approach could give these 
kinds of diseases a tool to discover new and effective biomarkers.
1.1. Diabetes
Diabetes, caused by several interactions between genetic and environmental factors, is a 
frequent disorder related to mutations in several genes, with each individual gene account-
ing for 1% of disease risk. In case of type 2 diabetes, dysfunction of multiple organ systems, 
including impaired insulin action in the muscle and adipose tissue, defective hepatic glucose 
production and insulin resistance are caused by loss of beta-cell mass and function. The dif-
ficult challenge for the understanding of the molecular pathways is evident, but progress in 
this area may be aided by the recent advent of technologies for metabolomic approach includ-
ing nuclear magnetic resonance or mass spectrometry.
Metabolomic could provide some advantages over other “omics” technologies in diabetes 
research: (1) The amount of metabolites or small molecules found and identified is less than 
the number of genes or proteins. So, the pathway interpretation should be easier and effec-
tive, as the results from genomics and proteomics. (2) Metabolomics is a tool for describing 
mechanisms of action and reverse effects of several treatments. However, metabolomics 
can be a science with limitations for technology misuse or data overinterpretation.
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Little information has been published about metabolic control of diabetic patients or their 
evolution with the treatment; for this reason, several profiles such as acylcarnitines, amino 
acids or cardiovascular markers, among them, should be studied taking into account recent 
metabolomic research for diabetes [1, 2]. Moreover, mitochondrial dysfunction and altered 
beta-oxidation of fatty acids have been described in diabetes [3].
A characteristic of all types of diabetes is that there are alterations in energy metabolism due 
to the lack of insulin action. This change is reflected especially in the metabolism of carnitine 
(Figure 2), which plays a major role as initiator of the beta-oxidation of fatty acids that occurs in 
the mitochondria. The investigation of the metabolic state of carnitine and its combination with 
the fatty acids and their metabolic intermediates produced during beta-oxidation seems essential 
to determine the degree of damage or the prognosis of these patients. Since it has been published 
that diabetic patients show carnitine deficiency and increased esterified carnitine [4], the study 
of the acylcarnitine composition compared to control group seems interesting, as well as the 
correlation of acylcarnitine composition with various complications which are expected during 
the course of the disease. These profiles of acylcarnitines can suggest incomplete beta-oxidation 
of long-chain fatty acids that can be amended with treatment. The carnitine and acylcarnitines 
can be analysed by means of their extraction from plasma or dried blood spots with an organic 
solvent, to remove proteins or solid-liquid extraction, respectively.
Figure 1. Experimental methodology involved in metabolomic studies of inborn errors of metabolism, where separation 
and detection phase could include a combination of gas chromatography, liquid chromatography and capillary 
electrophoresis with mass spectrometry.
A Metabolomics Approach to Metabolic Diseases
http://dx.doi.org/10.5772/65469
187
As some diabetic patients could suffer from alterations in energy metabolism, the study of 
creatine levels could be imperative to indicate a possible deficit of creatine to muscles or the 
brain. This creatine becomes creatine phosphate by a process of phosphorylation, leading to 
the genesis of ATP, essential in tissues with high-energy consumption, such as muscles and the 
brain through a process of dephosphorylation. An alteration of this metabolic pathway would 
lead to increase guanidinoacetate and a deficit in the production of creatine and, therefore, 
phosphocreatine.
In the absence of specific metabolic biomarkers of evolution and efficacy to treatment in dia-
betes, it should be performed a metabolic profile based on the profile of amino acids, which 
have been related to the methylation cycle and dementia (Met, Cys, Tau) in the diabetes.
l-Arginine, the main substrate of the endothelial nitric oxide synthase (NOS), is oxidised 
to l-citrulline and nitric oxide. Asymmetric dimethylarginine (ADMA) is derived from the 
proteolysis of proteins and acts as a competitive inhibitor of nitric oxide synthase, which 
is related to blood pressure, glucose intolerance, the thickness of the intima-media carotid, 
etc., making it a cardiovascular marker. It has been observed that the endothelial NO pro-
duction is reduced in diabetic patients at high cardiovascular risk partly due to the limita-
tion in the synthesis of arginine substrate and, secondly, because the ADMA, its inhibitor, 
is increased. So, it is proposed that the ADMA acts as a marker of cardiovascular risk in 
diabetic patients [5].
Epigenetics may contribute to metabolic study of diabetes through the global status of DNA 
methylation, which has been vaguely studied in this disease. Such mechanism methylation 
may play a role in the aetiology of monogenic diabetes. We propose the quantification of 
5-methylcytosine (5-mC) in order to study changes in the methylation of DNA/RNA or its 
possible degradation during the treatment.
1.2. Methylmalonic aciduria
Methylmalonic aciduria (MMA) is an inherited disorder involving certain amino acid and 
fatty acid metabolism. Levels of methylmalonic acid are increased mainly in urine. They are 
caused by an enzymatic deficiency of methylmalonyl-CoA mutase (MUT) in the mitochon-
dria or by a defect in the uptake, transport or synthesis of cobalamin, the cofactor of MUT. The 
management of this organic aciduria is based on a low-protein diet. MMA patient could suffer 
Figure 2. Molecular structure of carnitine, extracted from plasma by removing proteins.
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from renal failure as one of their critical problems, not common in other organic acidurias. 
However, the cause of renal failure and cardiovascular complications depends on several 
pathways. So, it is thought that nitric oxide formation could be affected causing endothelial 
dysfunction. Related to nitric oxide, arginine-asymmetric dimethylarginine (ADMA) path-
way, where ADMA acts as an inhibitor for nitric oxide synthase, should be described in these 
patients. ADMA levels are associated with an increase in cardiovascular events and chronic 
renal disease [6]. In addition, levels of the isomer symmetric dimethylarginine (SDMA) as a 
renal biomarker were also elevated in patients with chronic kidney disease.
Metabolic approach to evaluate the cardiovascular biomarker status should be recommended 
to improve the management for these patients. The objectives of this approach are also the 
identification and quantification of biomarkers of renal injury and inflammation such as inter-
leukins, tumour necrosis factor alpha (TNFα) and transforming growth factor beta (TGFβ), 
in patients who are at different stages of kidney damage. The definition of biomarkers for 
early renal impairment in MMA patient could assess changes in these parameters during the 
kidney damage progression.
The comparison of MMA subgroups at different stages of kidney damage would allow the 
identification of those markers of inflammation and tissue fibrosis involved in tubulointersti-
tial nephritis or primary glomerular injury and will establish a chronology on the appearance 
of altered levels of biomarkers for the development of kidney damage. Finally, we believe 
that greater understanding of the role of these molecules and inflammatory processes in the 
context of associated nephropathy by means of metabolomics is vital to facilitate the develop-
ment of novel targets and therapeutic nephroprotective strategies. The use of anti-inflamma-
tory molecules or antioxidants can be applied clinically successfully.
1.3. Non-arteritic anterior ischemic optic neuropathy (NAION)
The cause for optic neuropathy affecting elderly patients could be multifactorial and diffi-
cult to diagnose in case of non-arteritic anterior ischemic optic neuropathy (NAION). Few 
information has been published about metabolic pathways involved in this rare disease. So, 
the purpose of metabolomics is to suggest effective biomarkers and to describe metabolic 
fingerprinting.
Samples of patients and controls can be fingerprinted with liquid chromatography coupled 
to high-sensitive mass spectrometry, such as quadrupole time of flight (QTOF). According 
to Figure 1, data should be filtered, aligned and statistically analysed before identifying new 
compounds. These biomarkers were found to be significant in class separation and could be 
later confirmed by obtaining the characteristic MS/MS spectra and online databases, as Metlin 
or Human Metabolome Database. NAION patients presented differences in the phospholipid 
profile in comparison with controls, such as lower levels of lysoPCs.
LysoPCs and lysoPEs are products or metabolites of PCs and PEs (Figure 3), respectively, 
which are structural components of cell membranes. The structure of lysoPCs is a cho-
line polar group linked to fatty acyls that differ in chain length, position and degree of 
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 saturation. These compounds were extracted from blood samples by centrifugation, so 
protein precipitation was performed by adding 300 μL of cool methanol:ethanol (1:1) to 
the plasma. They were vortexed during 1 min and stored at −20 °C for 10 min. After cen-
trifugation, the supernatant can be injected in MS equipment. Increased levels of lysoPEs 
and reduced levels of lysoPCs can be a consequence of an altered choline phospholipid 
metabolism. The whole profile of lysoPCs has been published as a biomarker in other dis-
eases, though the type of the lysoPCs was not taken into account [7]. As lysoPC profile 
is a biomarker for other diseases, variations in some lysoPC isomers may not be enough 
in order to identify a specific disease. For this reason, individual lysoPC levels produced 
by a pathology should be further investigated. As it has been researched by our group, 
lysoPC profiling of plasma shows a characteristic profile in NAION patients: higher levels 
of lysoPEs and lower levels of lysoPCs. As PCs are methylated products of PEs, the hypoth-
esis for this result revolves around the poor methylation capacity in optic nerve cells. The 
characteristic profile of lysoPCs and lysoPEs also shows that the activity of phospholipases 
(PL) and lysophospholipases (LPL) could be increased [8].
NAION patients showed high levels of l-palmitoylcarnitine, which has the highest weight 
in the Partial Least Squares Discriminant Analysis (PLS-DA) prediction model (Figure 4). 
Nevertheless, these levels are not clearly related to the physiopathology of the disease 
because the uptake of acetylcarnitines by the mitochondria is a reversible process that is used 
to undergo mitochondrial β-oxidation of long-chain fatty acids and to transport acyl-coen-
zyme A from mitochondria to cytosol. So, more studies are necessary to confirm a disturbance 
in β-oxidation of fatty acid. However, these high levels of l-palmitoylcarnitine have been 
involved in the pathology of ischemia, acting as an inhibitor of cardiac Na,K-ATPase. Because 
of its amphipathic skill, palmitoylcarnitine can induce alterations in membrane fluidity and 
Figure 3. Molecular structure for phosphatidylcholine (PC) and phosphatidylethanolamine (PE), as the precursors or 
LysoPC and LysoPE.
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surface during apoptosis in NAION patients [9]. In this case, the membrane disturbance takes 
part in high-energy uptake cells of the optic nerve provoking severe blindness. This discus-
sion could signify that carnitine as a supplement could increase the in vivo regeneration of 
optic nerve cells after NAION event. Furthermore, due to identified profile by metabolomics 
and NAION physiopathology as central nervous system problem, it seems to be a stronger 
relationship between NAION disease and other ischemic processes, such as myocardial isch-
emia or ictus, than with neuropathological or ophthalmological syndromes.
1.4. Lysosomal diseases
The lysosomal diseases are another group of inherited metabolic disorders characterised by 
mutations in genes encoding lysosomal enzymes and proteins. The enzyme deficiencies cause 
impaired intracellular turnover and build-up of complex molecules including sphingolip-
ids, glycosaminoglycans and glycoproteins. These metabolites are established by metabolic 
approach as biomarkers. The pathology of lysosomal diseases is typically characterised by 
intra-lysosomal storage of a variety of substrates in multiple tissues and organs. Thus, the 
phenotypes of these disorders are complex and characterised by the variable association of 
visceral, skeletal and neurological manifestations.
The advancement in the diagnosis and treatment of lysosomal diseases has been largely 
stimulated by the improved knowledge on their molecular bases and pathophysiology. 
Metabolomics has a major role in this further impulse to the availability of technologies allow-
ing faster diagnosis. In the case of Fabry disease, caused by deficiency of α-galactosidase A, 
the glycosphingolipid accumulation in plasma and urine is used as biomarker. Two specific 
biomarkers have been identified and quantified in plasma and urine: globotriaosylceramide 
(Gb3) and globotriaosylsphingosine (lyso-Gb3). The search continues for biomarkers that 
might be reliable indicators of disease severity and response to treatment.
Figure 4. Partial Least Squares Discriminant Analysis (PLS-DA) scores plot of plasma metabolic profiles obtained from 
NAION patients and controls.
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Several metabolomic studies have been carried out for lysosomal diseases, such as Fabry [10] 
and Niemann-Pick [11] syndromes, to establish efficient biomarkers. For other lysosomal dis-
eases like mucopolysaccharidoses, these studies could be useful to identify the increase of a 
specific glycosaminoglycan in urine, such as dermatan sulphate, chondroitin sulphate, hepa-
ran sulphate and keratan sulphate [12].
2. Future progress
Nowadays, the metabolomics is continuously improving its methodology to obtain new bio-
markers quickly by means of advances in mass spectrometry and statistics software. So, it 
is clear that little-studied rare diseases, with no defined biomarkers, will be studied through 
this methodology. However, what is going to be an outstanding breakthrough is the combi-
nation of the information obtained by metabolomics, proteomics and genomics. Sometimes, 
these “omics” sciences are studied separately, but all information should be taken into account 
together in the future to understand the connexion of all information in the whole metabolic 
pathway.
3. Conclusions
It is evident that there is not a single perfect tool for global metabolic profiling. However, 
metabolomics, which combines sensitive analytical techniques with multivariate analysis, 
seems to be a good approach to identify biomarkers in diabetes and metabolic rare diseases, 
such as methylmalonic acidemia or lysosomal diseases.
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Appendices and nomenclatures
ADMA Asymmetric dimethylarginine
HMDB Human Metabolome Database
LysoPC Lysophosphatidylcholine
LysoPE  Lysophosphatidylethanolamine
MMA Methylmalonic acidurias
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NAION Non-arteritic anterior ischemic optic neuropathy
PC Phosphatidylcholine
PE Phosphatidylethanolamine
PLS-DA Partial least squares discriminant analysis
SDMA Symmetric dimethylarginine
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